Press releases | UCB
UCB's Global Corporate Website

This section is intended for media and financial analysts

Search Press releases

16 Dec 2021

Positive Top-Line Results for BIMZELX[®]▼(bimekizumab) in Phase 3 Ankylosing Spondylitis Trial

Read More
10 Dec 2021

UCB announces positive Phase 3 results for rozanolixizumab in generalized myasthenia gravis

Read More
3 Dec 2021

Disposals of own shares

Read More
3 Dec 2021

UCB to present new data at the American Epilepsy Society 75th Annual Meeting 2021 reinforcing long-standing commitment to advancing epilepsy treatment and care

Read More
2 Dec 2021

UCB Announces Global Partnership to Bring Disease-Modifying Therapies to People Living with Parkinson’s Disease

Read More
30 Nov 2021

UCB and Chiesi enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases

Read More

Stay up-to-date on the latest news and information from UCB

Subscribe